MBCOF (Marvel Biosciences) LT-Debt-to-Total-Asset: 1.32 (As of Apr. 2026)


MBCOF Marvel Biosciences Corp MBCOF
34 GF Score
Price $0.11
! 1 Warning Sign
View Full Analysis

What is Marvel Biosciences LT-Debt-to-Total-Asset?

Marvel Biosciences MBCOF 34 LT-Debt-to-Total-Asset is 1.32 as of Apr. 2026. GuruFocus rates MBCOF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Marvel Biosciences's long-term debt to total assests ratio for the quarter that ended in Apr. 2026 was 1.32.

Marvel Biosciences's long-term debt to total assets ratio declined from Apr. 2025 (1.42) to Apr. 2026 (1.32). It may suggest that Marvel Biosciences is progressively becoming less dependent on debt to grow their business.

Marvel Biosciences  (OTCPK:MBCOF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Marvel Biosciences LT-Debt-to-Total-Asset Related Terms

Marvel Biosciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Marvel Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences LT-Debt-to-Total-Asset Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.00 1.49 0.00 0.00

Marvel Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.42 0.00 0.00 0.00 1.32
MBCOF
34GF Score
Marvel Biosciences Corp MBCOF
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marvel Biosciences LT-Debt-to-Total-Asset Calculation

Marvel Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jul. 2025 is calculated as

LT Debt to Total Assets (A: Jul. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Jul. 2025 )/Total Assets (A: Jul. 2025 )
=0/0.239
=

Marvel Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Apr. 2026 is calculated as

LT Debt to Total Assets (Q: Apr. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Apr. 2026 )/Total Assets (Q: Apr. 2026 )
=0.454/0.343
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 1.32 mean?
Marvel Biosciences (MBCOF) has a LT-Debt-to-Total-Asset of 1.32 as of Apr. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Marvel Biosciences and its competitors.
Is Marvel Biosciences' LT-Debt-to-Total-Asset too high?
Marvel Biosciences' current LT-Debt-to-Total-Asset is 1.32. Overall, Marvel Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Marvel Biosciences' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Marvel Biosciences' LT-Debt-to-Total-Asset of 1.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Marvel Biosciences and its competitors. Marvel Biosciences's current LT-Debt-to-Total-Asset is 1.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marvel Biosciences stock overvalued right now?
Marvel Biosciences (MBCOF) has a current LT-Debt-to-Total-Asset of 1.32. The current LT-Debt-to-Total-Asset is 1.32. Marvel Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Marvel Biosciences (MBCOF), the current LT-Debt-to-Total-Asset is 1.32 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marvel Biosciences Business Description

Other Exchanges MRVL:Canada
Address 505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.
34GF Score

Get the complete analysis for MBCOF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price